Dashboard Tools Market News Investing Ideas Pricing
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Alterity Therapeutics Ltd banner

Alterity Therapeutics Ltd
SWB:PBN

Watchlist Manager
Alterity Therapeutics Ltd Logo
Alterity Therapeutics Ltd
SWB:PBN
Watchlist
Price: 0.2 EUR
Market Cap: €7.3B
Write Note Create Alert Ask AI

Wall St Price Targets

PBN Price Targets Summary
Alterity Therapeutics Ltd

Wall Street analysts forecast PBN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PBN is 0.38 EUR with a low forecast of 0.38 EUR and a high forecast of 0.4 EUR.

PBN Lowest Forecast
Wall Street Target
€0.38
90% Upside
PBN Average Forecast
Wall Street Target
€0.38
92% Upside
PBN Highest Forecast
Wall Street Target
€0.4
98% Upside
Lowest Forecast
Price Target
0.38 EUR
90% Upside
Average Forecast
Price Target
0.38 EUR
92% Upside
Highest Forecast
Price Target
0.4 EUR
98% Upside
Alterity Therapeutics Ltd Competitors:
Price Targets
TTD
Trade Desk Inc
106% Upside
JACK
Jack in the Box Inc
1% Upside
CIGI
Colliers International Group Inc
-2% Downside
CSGP
CoStar Group Inc
15% Upside
TTD
Trade Desk Inc
106% Upside
JACK
Jack in the Box Inc
1% Upside
CIGI
Colliers International Group Inc
-2% Downside
CSGP
CoStar Group Inc
15% Upside
CFFN
Capitol Federal Financial Inc
14% Upside

Revenue
Forecast

7% / Year
Past Growth
147% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
7% / Year
Past Growth
147% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 7%. The projected CAGR for the next 8 years is 147%.

What are analyst estimates?

Gross Profit
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Gross Profit Forecast
is not available for Alterity Therapeutics Ltd

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

What are analyst estimates?

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

What are analyst estimates?

Continue PBN Research

Summary
PBN intrinsic value, competitors valuation, and company profile.
DCF Valuation
PBN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PBN stock valuation using valuation multiples.
Wall St Estimates
PBN price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PBN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other Alterity Therapeutics Ltd listings:
NASDAQ • USD
ATHE
 OTC • USD
PRNAF
 ASX • AUD
ATH
 F • EUR
PBNN
 XBER • EUR
PBN
 F • EUR
PBN
 F • EUR
PBN0
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is PBN's stock price target?
Price Target
0.38 EUR

According to Wall Street analysts, the average 1-year price target for PBN is 0.38 EUR with a low forecast of 0.38 EUR and a high forecast of 0.4 EUR.

What is the Revenue forecast for Alterity Therapeutics Ltd?
Projected CAGR
147%

Over the last 13 years, the compound annual growth rate for Revenue has been 7%. The projected CAGR for the next 8 years is 147%.

Back to Top
ALPHA SPREAD
Follow us
Join 353,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett